<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1C702039-D041-41C7-97E6-22CA228D3CC0"><gtr:id>1C702039-D041-41C7-97E6-22CA228D3CC0</gtr:id><gtr:name>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Social Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1C702039-D041-41C7-97E6-22CA228D3CC0"><gtr:id>1C702039-D041-41C7-97E6-22CA228D3CC0</gtr:id><gtr:name>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3C2E4920-7D46-4F9E-9BE6-4F718C76EA14"><gtr:id>3C2E4920-7D46-4F9E-9BE6-4F718C76EA14</gtr:id><gtr:firstName>Julia</gtr:firstName><gtr:surname>del Amo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A7F1755C-E942-4737-9C36-9C9977371DB5"><gtr:id>A7F1755C-E942-4737-9C36-9C9977371DB5</gtr:id><gtr:firstName>Bruno</gtr:firstName><gtr:surname>Ledergerber</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2722AFF5-280D-4745-9B50-145872A74A75"><gtr:id>2722AFF5-280D-4745-9B50-145872A74A75</gtr:id><gtr:firstName>Mari</gtr:firstName><gtr:surname>Kitahata</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E4D96708-C40B-4B0A-A011-7EE2A61B9945"><gtr:id>E4D96708-C40B-4B0A-A011-7EE2A61B9945</gtr:id><gtr:firstName>Antonella</gtr:firstName><gtr:surname>d Arminio Monforte</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/830C1672-D746-4872-B04B-6FF35BC260FF"><gtr:id>830C1672-D746-4872-B04B-6FF35BC260FF</gtr:id><gtr:firstName>Amy</gtr:firstName><gtr:surname>Justice</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3D63A384-98EE-4C63-B7FF-A182D68F700A"><gtr:id>3D63A384-98EE-4C63-B7FF-A182D68F700A</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Sterne</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/65A15A0B-975F-4A60-BAFC-09378465160B"><gtr:id>65A15A0B-975F-4A60-BAFC-09378465160B</gtr:id><gtr:firstName>Matthias</gtr:firstName><gtr:surname>Egger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3D82D6C-A7CB-4D91-9FE2-D1E5B03CFF94"><gtr:id>E3D82D6C-A7CB-4D91-9FE2-D1E5B03CFF94</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:surname>Sterling</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4BB1F803-F380-444A-9841-092737061E15"><gtr:id>4BB1F803-F380-444A-9841-092737061E15</gtr:id><gtr:firstName>Francois</gtr:firstName><gtr:surname>Dabis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3440CF5-9B46-4FED-8783-C522D690E640"><gtr:id>E3440CF5-9B46-4FED-8783-C522D690E640</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Hogg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9056EA9-2D86-4BAC-85CC-34D81874F4F4"><gtr:id>C9056EA9-2D86-4BAC-85CC-34D81874F4F4</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Saag</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/903E6DFF-FE42-41C2-9250-DABD8695FAF0"><gtr:id>903E6DFF-FE42-41C2-9250-DABD8695FAF0</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:otherNames>Caroline</gtr:otherNames><gtr:surname>Lampe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BF77ADC2-E3BD-4013-973C-A944991B276B"><gtr:id>BF77ADC2-E3BD-4013-973C-A944991B276B</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Gill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B16E312A-BEFB-4F91-BB58-AD9C631EB3EB"><gtr:id>B16E312A-BEFB-4F91-BB58-AD9C631EB3EB</gtr:id><gtr:firstName>Jodie</gtr:firstName><gtr:surname>Guest</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB8777EA-55BC-48D2-B979-75F55204ECF0"><gtr:id>FB8777EA-55BC-48D2-B979-75F55204ECF0</gtr:id><gtr:firstName>Frank</gtr:firstName><gtr:surname>de Wolf</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62A5B14F-156F-4F9E-980D-75EDE4EA15FD"><gtr:id>62A5B14F-156F-4F9E-980D-75EDE4EA15FD</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:surname>May</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5D0DD6B8-EEC5-4040-9320-92F6CB776CE8"><gtr:id>5D0DD6B8-EEC5-4040-9320-92F6CB776CE8</gtr:id><gtr:firstName>Gerd</gtr:firstName><gtr:surname>Fatkenheuer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7B2E8F8E-2B1C-4AF0-BB50-7DC552D05763"><gtr:id>7B2E8F8E-2B1C-4AF0-BB50-7DC552D05763</gtr:id><gtr:firstName>Dominique</gtr:firstName><gtr:surname>Costagliola</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90BED700-2EEA-47C5-A276-1077B8B68D48"><gtr:id>90BED700-2EEA-47C5-A276-1077B8B68D48</gtr:id><gtr:firstName>Amanda</gtr:firstName><gtr:otherNames>Jayne</gtr:otherNames><gtr:surname>Mocroft</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5CD86292-EA6C-40A9-9C4A-62FF5F2A720C"><gtr:id>5CD86292-EA6C-40A9-9C4A-62FF5F2A720C</gtr:id><gtr:firstName>Jordi</gtr:firstName><gtr:surname>Casabona</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700820"><gtr:id>16802387-B3D2-4291-BCD4-95B01099538E</gtr:id><gtr:title>Monitoring and modelling prognosis in the era of HAART (Extension to Strategic Grant G0100221)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700820</gtr:grantReference><gtr:abstractText>Highly effective treatments, consisting of a combination of different drugs, are now available for people infected with HIV. These treatments have dramatically reduced the risk of acquired immune deficiency syndrome (AIDS) and the risk of death. Since 1996, when these treatments became available, causes of death among adults dying with or due to HIV-infection have changed. The aim of the ART Cohort Collaboration (ART-CC) is to study rates of serious diseases and death in HIV-infected patients who have started combination therapy. The collaboration is coordinated by a small team at Bristol University, and admininistered by a steering committee of cohort representatives. Our most recent dataset contains data on 45,000 HIV-infected individuals combined from 16 cohort studies (studies in which HIV-infected individuals have been followed over time). The present grant covers the period February 2008 to January 2011. Our objectives are (1) To describe the risk of AIDS, AIDS-defining illnesses and deaths from all causes and specific causes in patients starting combination therapy; (2) To define groups of illnesses that have similar implications for the subsequent risk of death, and to propose a classification of these illnesses that is relevant now that effective treatments are available; (3) To examine causes of death in the era of effective treatment, and death rates compare with the general population; (4) To use data from both cohort studies and clinical trials to compare different drug regiments; (5) To examine how outcomes differ between regions, studies, and settings and to conduct comparisons with a sister collaboration in low-income countries. We will derive updated datasets twice during the period covered by the present application. An expert committee will classify causes of death. We will compare mortality rates in HIV-infected individuals with those in the general population. The results of this research will be of direct relevance to the care of HIV-infected patients.</gtr:abstractText><gtr:technicalSummary>Highly active antiretroviral therapy (HAART) has substantially improved the prognosis of HIV-infected patients, but has to be continued indefinitely once initiated. 90% of HIV-infected people live in resource-poor settings. HAART has resulted in a shift in the causes of death among adults dying with or due to HIV-infection. Randomized controlled trials (RCTs) of antiretroviral drugs typically examine differences or equivalence in short-term surrogate markers: the extent to which such effects can be extrapolated to clinical outcomes is unclear.

The aim of the ART Cohort Collaboration (ART-CC) is to examine the prognosis of HIV-infected, antiretroviral-na?ve patients starting HAART, with a focus on clinical events (AIDS-defining conditions, death and cause-specific mortality). The collaboration is coordinated by a small team at Bristol University, and admininistered by a steering committee of cohort representatives. Our most recent dataset contains data on 45,000 HIV-infected individuals combined from 16 cohort studies. In the present proposal, we request funding from February 2008 to January 2011.

Our objectives are (1) To describe the risk of progression to AIDS, AIDS-defining events (ADEs), and deaths from all causes and specific causes in treatment na?ve patients starting HAART; (2) To define groups of ADEs with comparable prognostic significance, and to propose a classification for the HAART era; (3) To examine causes of death in the era of HAART, and how cause-specific and all-cause mortality compare with the general population; (4) To examine the relationship between the effects of different HAART regimens on short-term, surrogate outcomes and those on longer term clinical outpoints; (5) To examine how outcomes differ between regions, cohorts, and settings and to conduct comparisons with a sister collaboration in low-income countries.

We will derive updated datasets twice during the period covered by the present application. The development of prognostic models will use our previously published methods. We will examine the prognostic importance of different AIDS-defining events for subsequent mortality. An expert committee will classify causes of death. We will use actuarial methods to compare mortality rates in HIV-infected individuals with those in the general population. We will compare the estimated effects of different initial HAART regimens using data from both RCTs and ART-CC. We will use meta-analytic approaches to examine heterogeneity between regions, cohorts and settings. The results of this research will be of direct relevance to the care of HIV-infected patients.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>623125</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Alabama at Birmingham</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CNICS</gtr:description><gtr:id>155196DF-A1C5-4AC2-92A0-D96540A1610E</gtr:id><gtr:impact>dataset</gtr:impact><gtr:outcomeId>PrAveMjRkya-1</gtr:outcomeId><gtr:partnerContribution>Data contributed to opportunistic infection modelling.</gtr:partnerContribution><gtr:piContribution>Statistical modelling.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Copenhagen HIV Programme (CHIP)</gtr:department><gtr:description>COHERE</gtr:description><gtr:id>2802EEDC-A27C-4A92-B391-B8FB97376DCE</gtr:id><gtr:impact>Published papers by ART-CC used data managed by COHERE.</gtr:impact><gtr:outcomeId>ZccMrwcLaw1-2</gtr:outcomeId><gtr:partnerContribution>Management of database and scientific advice.</gtr:partnerContribution><gtr:piContribution>Scientific advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:collaboratingOrganisation><gtr:country>Central African Republic</gtr:country><gtr:department>IeDEA West Africa Region</gtr:department><gtr:description>IeDEA West Africa</gtr:description><gtr:id>3F84A68F-3DA1-4F6B-8DCA-DECF1EA22E39</gtr:id><gtr:impact>Paper in Press</gtr:impact><gtr:outcomeId>eYEDJiiiau9-1</gtr:outcomeId><gtr:partnerContribution>Prognostic modelling methodology for HIV-1 and HIV-2 modelling</gtr:partnerContribution><gtr:piContribution>Prognostic modelling methodology for HIV-1 and HIV-2 modelling</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>IeDEA Southern Africa</gtr:description><gtr:id>859C5879-D830-4D53-9885-3CE94EC46F44</gtr:id><gtr:impact>publications as listed.</gtr:impact><gtr:outcomeId>kAftf4mQq9M-1</gtr:outcomeId><gtr:partnerContribution>Data and statistical modelling.</gtr:partnerContribution><gtr:piContribution>Prognostic modelling for pediatric HIV patients and comparative prognosis for adults comparing mortality with Europe and North America.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard T.H. Chan School of Public Health</gtr:department><gtr:description>HIV-CAUSAL</gtr:description><gtr:id>D20B386D-05C0-4883-8F14-69E16881C235</gtr:id><gtr:impact>Paper of effect of ART.</gtr:impact><gtr:outcomeId>D6PjX1QegRE-1</gtr:outcomeId><gtr:partnerContribution>Data and statistical modelling.</gtr:partnerContribution><gtr:piContribution>Statistical modelling and data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Johns Hopkins Bloomberg School of Public Health</gtr:department><gtr:description>NA-ACCORD</gtr:description><gtr:id>8F0B7CA2-C8C8-4F96-B0A4-8E118F350D9F</gtr:id><gtr:impact>dataset</gtr:impact><gtr:outcomeId>HuZrmPBTuRx-1</gtr:outcomeId><gtr:partnerContribution>Data for project on opportunistic infections</gtr:partnerContribution><gtr:piContribution>Statistical modelling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Population Health Sciences</gtr:department><gtr:description>UKCHIC</gtr:description><gtr:id>96D43BCA-2130-4056-A214-673C72677438</gtr:id><gtr:impact>2 life expectancy papers
subtypes paper in press with AIDS</gtr:impact><gtr:outcomeId>56aa36cca08e98.36373926-1</gtr:outcomeId><gtr:partnerContribution>Supplied data, expertise on HIV.</gtr:partnerContribution><gtr:piContribution>Collaboratively worked on 2 studies on life expectancy of people treated for HIV infection. Analysed data, wrote papers, and presented at conferences. Collaborated on subtypes analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERN (1053) (Universit? Bordeaux Segalen)</gtr:department><gtr:description>COHERE</gtr:description><gtr:id>E6924F74-207A-451D-99BB-C6989C03D6B4</gtr:id><gtr:impact>Published papers by ART-CC used data managed by COHERE.</gtr:impact><gtr:outcomeId>ZccMrwcLaw1-1</gtr:outcomeId><gtr:partnerContribution>Management of database and scientific advice.</gtr:partnerContribution><gtr:piContribution>Scientific advice.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>IEDEA South Africa</gtr:description><gtr:id>9AA247A5-2D22-4DAC-A39F-5BB03B11D9CD</gtr:id><gtr:impact>IEDEA South Africa is a collaboration of HIV clinic cohorts in Sub Saharan Africa, funded by the US National Institutes of Health, with which we collaborate closely. The following publications have resulted from this collaboration: 18981768, 18670668, 18373510, 18240981, 19142294</gtr:impact><gtr:outcomeId>1473A51093A-1</gtr:outcomeId><gtr:partnerContribution>Comparative analyses of data from low and high income settings</gtr:partnerContribution><gtr:piContribution>The IEDEA collaboration is a global network of HIV cohort collaborations funded by the US National Institutes of Health. Sterne and May are collaborators with the IEDEA Southern Africa collaboration (Principal Investigator Matthias Egger)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>IeDEA Southern Africa</gtr:description><gtr:id>6687AF1C-00D3-4963-B537-88EF6607E3D8</gtr:id><gtr:impact>publications as listed.</gtr:impact><gtr:outcomeId>kAftf4mQq9M-2</gtr:outcomeId><gtr:partnerContribution>Data and statistical modelling.</gtr:partnerContribution><gtr:piContribution>Prognostic modelling for pediatric HIV patients and comparative prognosis for adults comparing mortality with Europe and North America.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference on Retroviruses and Opportunistic Infections</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9C530B50-8A1D-42F4-96DD-199594144AA2</gtr:id><gtr:impact>Attended the Conference on Retroviruses and Opportunistic Infections every year to present work, support team members and lead the ART-CC collaboration in its work on HIV-1 patients. This is a major, international conference with an audience of around 4,000 researchers in the field of opportunistic infections and retroviruses.</gtr:impact><gtr:outcomeId>56bdb8f74ba456.51083378</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.croiconference.org/</gtr:url><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media appearances</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>53A489CF-8D8E-4B08-BEE7-BAC8D9E6B317</gtr:id><gtr:impact>Television and radio appearances by Sterne, describing improved life expectancy of HIV-infected individuals, following publication of article in the Lancet (18657708)

Wider knowledge of the benefits of antiretroviral therapy</gtr:impact><gtr:outcomeId>FBE2921E494</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press coverage</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>93C51973-46BE-4BFB-B9F6-80B084293F5A</gtr:id><gtr:impact>Press releases from BMJ, British HIV Association and Bristol University after publication of paper on life expectancy in BMJ (pubmed 21990260). These resulted in 2 page artice in the Independent, article in Bristol Evening Post, front page item on BBC news website, Reuters articles (India and China), Nursing Times, National AIDS Treatment Advocacy Project (USA), Twitter and numerous other coverage on internet newsletters.

Wider knowledge of impact of late diagnosis and treatment on life expectancy on those with HIV. This should translate into increased testing for HIV and earlier treatment at higher CD4 counts with improved survival.</gtr:impact><gtr:outcomeId>AGiQX17Ydxb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interviews</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C2637692-1801-4377-B0E4-A547157736A5</gtr:id><gtr:impact>Two radio interviews by May in news programmes on subject of life expectancy in HIV positive individuals after publication of paper in BMJ (pubmed 21990260).

Wider knowledge of the benefits of testing and diagnosis early in the course of HIV disease so yhat antiretroviral therapy can be received in accordance with guidelines and lengthen life expectancy.</gtr:impact><gtr:outcomeId>jGLzt5FUBuw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press conference</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5A8BDCE4-4168-4033-9AD8-8AB6EBDED320</gtr:id><gtr:impact>Appeared at a press conference during the 2009 Conference on Retrovirus and Opportunistic Infections, to describe work examining when HIV-infected individuals should start antiretroviral therapy

Coverage on several web sites providing information to HIV infected patients</gtr:impact><gtr:outcomeId>0BAAA33C447</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>568241</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F0004C21-E1E8-463D-95E4-561BD75B4117</gtr:id><gtr:outcomeId>ZhrfvbQhP2F0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DHHS Panel on Antiretroviral Guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents</gtr:guidelineTitle><gtr:id>594BEA5A-7F49-4236-B8BF-B86BF8AE0B6C</gtr:id><gtr:impact>The most recent US guidelines on antiretroviral therapy for HIV-infected individuals cite papers from the ART Cohort Collaboration, including and extensive discussion of our 2009 Lancet paper on timing of antiretroviral therapy (19361855) and our 2007 paper on 5 year prognosis (17502729)</gtr:impact><gtr:outcomeId>747934642DD</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US HIV treatment guidelines</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel</gtr:guidelineTitle><gtr:id>E7C11C7A-8CCF-490B-A8FA-EA8BF9468FFD</gtr:id><gtr:impact>Our work was cited in US guidelines on treatment of HIV-infected individuals</gtr:impact><gtr:outcomeId>5F99D5F7342</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Our website at www.art-cohort-collaboration.org provides a prognostic model for use by patients and their carers.</gtr:description><gtr:id>E5416804-00BB-4610-A4E3-CFE99A5FB1B3</gtr:id><gtr:impact>The web site has been accessed tens of thousands of times</gtr:impact><gtr:outcomeId>B8CA743F2EE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Prognostic model</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://www.art-cohort-collaboration.org</gtr:url><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AE75D2C9-8026-46B5-A8EF-6F9E8E0A65D1</gtr:id><gtr:title>Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4636179c9d21cbc8d884847bab3c4050"><gtr:id>4636179c9d21cbc8d884847bab3c4050</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56c1ffef3f4fe1.45848088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF6F60E3-9F6B-416C-A215-3D27355A4FA6</gtr:id><gtr:title>Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58b8564f9b5eee1b537754e2687f762b"><gtr:id>58b8564f9b5eee1b537754e2687f762b</gtr:id><gtr:otherNames>When To Start Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>3E1B02D4AF9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9D7B2B5-97ED-426A-A777-A9C680A82CB6</gtr:id><gtr:title>Immunologic response in treatment-na&amp;iuml;ve HIV-2-infected patients: the IeDEA West Africa cohort.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b149344ba5fe078eb0f5bf9bd1cd8f95"><gtr:id>b149344ba5fe078eb0f5bf9bd1cd8f95</gtr:id><gtr:otherNames>Balestre E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>56c3414aaa57a6.06433657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E179607D-06AE-43E7-8279-C405342D1969</gtr:id><gtr:title>Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f75d64af3a046753f0fbd3b32aab3b"><gtr:id>70f75d64af3a046753f0fbd3b32aab3b</gtr:id><gtr:otherNames>Trickey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>582f15f192f371.27318995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F78086C-5AC6-408C-8587-355D99B1C448</gtr:id><gtr:title>Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fbf3c9de6cb390e73a7d1bfa25f1283"><gtr:id>4fbf3c9de6cb390e73a7d1bfa25f1283</gtr:id><gtr:otherNames>Harris RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>ABC9DFDB5BB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7595139-499E-4C62-8776-68DF67375AB2</gtr:id><gtr:title>Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4636179c9d21cbc8d884847bab3c4050"><gtr:id>4636179c9d21cbc8d884847bab3c4050</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>E980C8E8C58</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EF5DCF0-59A1-481C-A9B5-F3A52247D2D2</gtr:id><gtr:title>Determinants of Waiting Times for ART in the Free State Province, South Africa</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db2417bd1e9824844bae1de5235a57c6"><gtr:id>db2417bd1e9824844bae1de5235a57c6</gtr:id><gtr:otherNames>Ingle, S.M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>56c20280bcabd0.56132334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3039BFE-0C22-4545-8507-7BD898F4386B</gtr:id><gtr:title>Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1119906f8730f03f0316ea0b9cb5b36"><gtr:id>f1119906f8730f03f0316ea0b9cb5b36</gtr:id><gtr:otherNames>Hogg Robert</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56a76e664f9817.91370907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8EC447B-3DFA-4683-B05F-C80DC530C7DD</gtr:id><gtr:title>Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>Mv9fp85gsL6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCE41187-57E7-43CC-BC66-2D0BE1BAF44A</gtr:id><gtr:title>Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies</gtr:title><gtr:parentPublicationTitle>The Lancet HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f75d64af3a046753f0fbd3b32aab3b"><gtr:id>70f75d64af3a046753f0fbd3b32aab3b</gtr:id><gtr:otherNames>Trickey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>594ba6f5116186.82560351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD8BE6C2-1DDA-4789-AB71-30D673F0726B</gtr:id><gtr:title>Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a06e55f228cd5a3efbb188f76736071"><gtr:id>1a06e55f228cd5a3efbb188f76736071</gtr:id><gtr:otherNames>HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_12961_21_22869294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CC347D4-5E1F-4150-897A-413C22469BD3</gtr:id><gtr:title>Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/628876c9fd50086d424d3939e9b327dc"><gtr:id>628876c9fd50086d424d3939e9b327dc</gtr:id><gtr:otherNames>Ingle SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_540e155e155a5be89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B81524BE-D5B1-45C5-85C1-508003A816ED</gtr:id><gtr:title>Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90919db394f928c9096116755d098dfe"><gtr:id>90919db394f928c9096116755d098dfe</gtr:id><gtr:otherNames>Nash D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>29301644A37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8F539BF-9D49-4FF8-9511-EBCF2B5A86BA</gtr:id><gtr:title>Mortality of HIV-1-infected Patients Starting ART in Sub-Saharan Africa: The IeDEA Prognostic Model</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daf40f9d812f3b78a8fa25bea666f0f6"><gtr:id>daf40f9d812f3b78a8fa25bea666f0f6</gtr:id><gtr:otherNames>May, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>56c202deed7e11.59596504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA22D668-39E1-4F2E-82C0-6C8B0ED6248B</gtr:id><gtr:title>Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/440cbe8115805a4c83702556d9fc2e7c"><gtr:id>440cbe8115805a4c83702556d9fc2e7c</gtr:id><gtr:otherNames>Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>CE3C324FA33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EB5451C-AD88-4048-BBF6-29048CCDF967</gtr:id><gtr:title>Long-term mortality in HIV-positive individuals virally suppressed for &amp;gt;3 years with incomplete CD4 recovery.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5754a6c189699f93dc0d4ebf6bd186d"><gtr:id>a5754a6c189699f93dc0d4ebf6bd186d</gtr:id><gtr:otherNames>Engsig FN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>doi_55faa1aa1cb276a4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C6EAB3E-A9FC-49D5-9654-063C6FE9EEBA</gtr:id><gtr:title>Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f51f97ab5cbecafed932b0d33893219c"><gtr:id>f51f97ab5cbecafed932b0d33893219c</gtr:id><gtr:otherNames>Forster M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>8DF9EDA7584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0177D4E2-6101-47F9-AD09-636A2B45889C</gtr:id><gtr:title>Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d93c3705563a63508cbc695a152a149"><gtr:id>0d93c3705563a63508cbc695a152a149</gtr:id><gtr:otherNames>Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>K9X5iwcVsaH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C987DA49-4B9A-41C2-A239-397A6E9C4E1D</gtr:id><gtr:title>Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d420c3494b3462258a04c9a0276a156"><gtr:id>4d420c3494b3462258a04c9a0276a156</gtr:id><gtr:otherNames>Justice AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>aiXTqgL5tRd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CE2BCA1-63C6-4F54-A92F-103899BF9C1F</gtr:id><gtr:title>Prognosis of HIV-1-infected Patients Starting ART in Sub-Saharan Africa: A Collaborative Analysis of Scale-up Programs</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daf40f9d812f3b78a8fa25bea666f0f6"><gtr:id>daf40f9d812f3b78a8fa25bea666f0f6</gtr:id><gtr:otherNames>May, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>56c1ff5b71a5c7.73169236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9CED373-2CAC-498E-BB63-22602EC126C6</gtr:id><gtr:title>Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc7ab20f7fe0f1bdf64047ca4f189277"><gtr:id>bc7ab20f7fe0f1bdf64047ca4f189277</gtr:id><gtr:otherNames>Tuboi SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>o6NTF2VUTTy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>578C221B-AB41-4476-A72F-7B9A857C44B4</gtr:id><gtr:title>Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5675e1f2f2821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C939515B-E74B-41D6-9C5F-B481628797BB</gtr:id><gtr:title>Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>doi_55f9849846f34ceb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>138D5364-155D-4A18-BF7D-EE7602DB2ACE</gtr:id><gtr:title>Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5679449552ea83.55321923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE87CC2F-ED62-4CD2-8671-9E756227ED7F</gtr:id><gtr:title>Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>A500310ED6C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FF164EC-4683-4AD9-AF98-F1C6ED06EED0</gtr:id><gtr:title>Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2573d266ee79ea0e1dea09c9c3047865"><gtr:id>2573d266ee79ea0e1dea09c9c3047865</gtr:id><gtr:otherNames>Mugavero MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>jFrE1GCbg4H</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82D6A2AF-1953-4018-AAB1-69CD09121C71</gtr:id><gtr:title>Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration.</gtr:title><gtr:parentPublicationTitle>Journal of women's health (2002)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ee2bab53379aeb12dd7a47feb47a0b6"><gtr:id>6ee2bab53379aeb12dd7a47feb47a0b6</gtr:id><gtr:otherNames>Braitstein P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1540-9996</gtr:issn><gtr:outcomeId>69ADAF50996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C1C7FAA-09D5-4459-9727-3485C7E7B232</gtr:id><gtr:title>Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60de1a7fff68e74c6c5f14855ea07fa7"><gtr:id>60de1a7fff68e74c6c5f14855ea07fa7</gtr:id><gtr:otherNames>Moore DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>77DA25298C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54791986-972E-4425-ABAB-1C53001DF841</gtr:id><gtr:title>HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4? T-cell lymphocytes.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b35340358bbbebb9556bf6735ac74fb5"><gtr:id>b35340358bbbebb9556bf6735ac74fb5</gtr:id><gtr:otherNames>Bohlius J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>LqaJzKUqZBF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF578DBF-572F-4D58-99DA-F1F5F5AB5C19</gtr:id><gtr:title>Life expectancy of HIV-positive adults: a review.</gtr:title><gtr:parentPublicationTitle>Sexual health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1448-5028</gtr:issn><gtr:outcomeId>cvLTC8ZGkWe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E645413D-CCDF-4FE5-94B4-F1220A19E558</gtr:id><gtr:title>Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>pm_540e137e137a49027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0A9602E-C56C-4676-928E-5E022D30A960</gtr:id><gtr:title>Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5675dfcba3dc8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4115AC1D-34CD-42D6-86D2-76F55798E355</gtr:id><gtr:title>Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>doi_55faa1aa1cc533a1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D4EAD45-0894-42B6-BBE8-7D06B5E5F718</gtr:id><gtr:title>Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28d260b2a011eb911cd6334e1baf2501"><gtr:id>28d260b2a011eb911cd6334e1baf2501</gtr:id><gtr:otherNames>Brinkhof MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>03565C82E42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D190B9AE-9837-475A-9CB1-5977653A8671</gtr:id><gtr:title>Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5847d8ffb1ef42.17617139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7004983-936F-48A6-BD32-74E636D6756D</gtr:id><gtr:title>Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2b6ce2bc7281ddef0c5ea2af71f7e7e"><gtr:id>e2b6ce2bc7281ddef0c5ea2af71f7e7e</gtr:id><gtr:otherNames>Kaulich-Bartz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12961_21_23449349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55576C87-8697-459B-AE5D-BE78D79D8AB4</gtr:id><gtr:title>Outcomes of Abacavir and Efavirenz based HAART: Comparison of ACTG 5095 Trial Results with Observational Cohort Studies</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5f0dcef4396fbf5bc3b6b0e7388179c"><gtr:id>b5f0dcef4396fbf5bc3b6b0e7388179c</gtr:id><gtr:otherNames>Mugavero, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>56c20330763c57.52663378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5898A6D-AB90-464C-BDE4-FBDC20F6EF4A</gtr:id><gtr:title>Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d935415403bb2b7827a6d35549c0c66"><gtr:id>7d935415403bb2b7827a6d35549c0c66</gtr:id><gtr:otherNames>Boulle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5463bc97058819.78757685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3152B612-D417-4925-89AD-F01ED98F4329</gtr:id><gtr:title>CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>JfwwJo5EP7Q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BBA75A4-DB82-4936-B255-181C04CCA54C</gtr:id><gtr:title>When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>pm_12961_21_21502648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DECC802-0661-40A8-89C5-57E21718E66A</gtr:id><gtr:title>Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_540e155e1559a8dbf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B007ECA5-82C8-44DF-958A-7C2F047A3DD2</gtr:id><gtr:title>Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/628876c9fd50086d424d3939e9b327dc"><gtr:id>628876c9fd50086d424d3939e9b327dc</gtr:id><gtr:otherNames>Ingle SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>qme9oXnTyCp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59193721-9801-40B9-A0F0-ADF0F42C60D6</gtr:id><gtr:title>Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a744825f6bbc9b0436da322f6538ce2"><gtr:id>4a744825f6bbc9b0436da322f6538ce2</gtr:id><gtr:otherNames>antiretroviral therapy cohort collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>C6BDFF6E7A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAB928EE-F078-4782-90C3-BF619D5BD7F2</gtr:id><gtr:title>CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f75d64af3a046753f0fbd3b32aab3b"><gtr:id>70f75d64af3a046753f0fbd3b32aab3b</gtr:id><gtr:otherNames>Trickey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a70f16173d195.37480672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>602536E5-1CAE-41DE-9D21-B8180B74488D</gtr:id><gtr:title>Cumulative incidence of and risk factors for changes to first ART regimen and death prior to a change: the Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1efdda13511cb84b95a40a6f093861"><gtr:id>8d1efdda13511cb84b95a40a6f093861</gtr:id><gtr:otherNames>Abgrall, S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56c1fc9abdf7d9.41960525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65AA3DCD-015F-40B9-A438-F58FB26F2DDF</gtr:id><gtr:title>When to Start ART</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7ddcd487f09db4186cd29b6c9a89a65"><gtr:id>a7ddcd487f09db4186cd29b6c9a89a65</gtr:id><gtr:otherNames>STERNE, J.A.C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>56c338284279b5.79321327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5276991D-09D2-41B2-885F-9CF844DE3359</gtr:id><gtr:title>Does short-term virologic failure translate to clinical events in antiretroviral-na&amp;iuml;ve patients initiating antiretroviral therapy in clinical practice?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>D5394928ED1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2098FC7-7AE8-4AA2-91BD-E128B455F6AC</gtr:id><gtr:title>Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcdb6bf35dccf2dd1717561b55531586"><gtr:id>bcdb6bf35dccf2dd1717561b55531586</gtr:id><gtr:otherNames>Fox MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_12961_21_22433846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1FB5D1E-410A-41C1-8A43-6D854DC4F21F</gtr:id><gtr:title>Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ca1a8c279e48d4c8dcd5f4c2e967753"><gtr:id>1ca1a8c279e48d4c8dcd5f4c2e967753</gtr:id><gtr:otherNames>Pettit AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a679508413b16.58362279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B99E3442-F109-42F5-95EF-112FF4E9D8CD</gtr:id><gtr:title>Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4636179c9d21cbc8d884847bab3c4050"><gtr:id>4636179c9d21cbc8d884847bab3c4050</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>F11F2855C39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED9F5CA2-666C-488B-B02C-96FF0E67F00E</gtr:id><gtr:title>Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression</gtr:title><gtr:parentPublicationTitle>JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf150b5b41cc50546c427a0bc92079af"><gtr:id>bf150b5b41cc50546c427a0bc92079af</gtr:id><gtr:otherNames>Moore David M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56a76b3c6ff957.50846763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D70043F0-89B2-4343-8F57-3EA289576980</gtr:id><gtr:title>Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a56fd17e523927a5a7e37f9096eda128"><gtr:id>a56fd17e523927a5a7e37f9096eda128</gtr:id><gtr:otherNames>ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>335B2C2ADBF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E74B55B2-55E9-40BB-9449-3236BE42B2A3</gtr:id><gtr:title>Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>56aa39884f2027.04530712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE0E891A-2BB3-4DF4-A718-8DC154BBE63D</gtr:id><gtr:title>Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6ae03c008ef872b61775b9202c479d6"><gtr:id>d6ae03c008ef872b61775b9202c479d6</gtr:id><gtr:otherNames>Hernando V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12961_21_22410685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF87EB41-E014-4492-89D4-553611B00192</gtr:id><gtr:title>Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a0b2053d0226a3b151c239c08c11329"><gtr:id>1a0b2053d0226a3b151c239c08c11329</gtr:id><gtr:otherNames>Helleberg M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55faa2aa243aa69f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3278863F-8C2C-4E76-98E5-2185C45F0AF9</gtr:id><gtr:title>Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42d152938bf229c1e5f6d40857170522"><gtr:id>42d152938bf229c1e5f6d40857170522</gtr:id><gtr:otherNames>IeDEA and ART Cohort Collaborations</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_540e155e1558ef38e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BBBC0D0-D01E-48AA-ABA5-8F45796F5C3B</gtr:id><gtr:title>An internationally generalizable risk index for mortality after one year of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40dc33df2adbb2397e9dbe8fbc9303ae"><gtr:id>40dc33df2adbb2397e9dbe8fbc9303ae</gtr:id><gtr:otherNames>Tate JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12961_21_23095314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>699FB422-75AF-4A4D-912E-2021529B90E3</gtr:id><gtr:title>Pre-treatment Mortality and Probability of Starting ART in Patients Enrolled in the Free State ARV Program, South Africa: Implications for Treatment Guidelines</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db2417bd1e9824844bae1de5235a57c6"><gtr:id>db2417bd1e9824844bae1de5235a57c6</gtr:id><gtr:otherNames>Ingle, S.M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>56c1fe88a64ba1.53047733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45FD4300-250C-47CB-9B65-DC08153DA60B</gtr:id><gtr:title>Differences in access and patient outcomes across antiretroviral treatment clinics in the Free State province: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/628876c9fd50086d424d3939e9b327dc"><gtr:id>628876c9fd50086d424d3939e9b327dc</gtr:id><gtr:otherNames>Ingle SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>ZgCwSpGpZsK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECC6D526-B70E-4BE6-B741-E1BD55FE9FC8</gtr:id><gtr:title>Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cb99db5b22ef00de17a26a8de1511e9"><gtr:id>7cb99db5b22ef00de17a26a8de1511e9</gtr:id><gtr:otherNames>Ch?ne G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>586e6c7def0782.71812237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ED51462-C254-4550-84C3-07B3D34DBAF9</gtr:id><gtr:title>The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12961_21_22546987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0C54D6E-74E0-4BE4-9ED3-1D4F5C38B90C</gtr:id><gtr:title>Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>56794912922757.95790959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4649849F-DC50-4890-8ED5-7CE149249957</gtr:id><gtr:title>Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_12961_21_23457077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7639D6A-9CB9-47C9-8D55-FA9803981C7C</gtr:id><gtr:title>Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/197ad22db7b87dd4874b260f40c9d828"><gtr:id>197ad22db7b87dd4874b260f40c9d828</gtr:id><gtr:otherNames>Abgrall S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5450c117f03222.72916958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C880E980-6AD7-43FF-926E-CB74926FB864</gtr:id><gtr:title>How early to start: what do observational data suggest?</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdac88a583371e15672a469c38473312"><gtr:id>cdac88a583371e15672a469c38473312</gtr:id><gtr:otherNames>Sterne J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>56c337e0f3bb00.70770370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A784F16-C54D-4C36-A9F9-B3F19DB947D0</gtr:id><gtr:title>Immunodeficiency at the start of ART: Global view</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82a9a381de2ab654051026a00cf70fe8"><gtr:id>82a9a381de2ab654051026a00cf70fe8</gtr:id><gtr:otherNames>Mugglin, C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56c1fd38d05da9.74078069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC1E32D-8D42-4272-B1B5-772B423F8127</gtr:id><gtr:title>Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5675da3fdbc98</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64BB8608-57AA-42D7-9EED-55148F2D8E6E</gtr:id><gtr:title>The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6f0453a121999165934fdb45d5f7914"><gtr:id>f6f0453a121999165934fdb45d5f7914</gtr:id><gtr:otherNames>Murray M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>DB3isVcHDXH</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700820</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>